Welcome to our dedicated page for Ikena Oncology SEC filings (Ticker: IKNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding a clinical-stage biotech like Ikena Oncology isn’t easy—hundreds of pages detail complex signaling science, shifting R&D spend, and cash runway projections. If you have ever asked, “Ikena Oncology SEC filings explained simply” or searched for “understanding Ikena Oncology SEC documents with AI,” you already know the challenge.
Stock Titan’s platform turns that challenge into clarity. Our AI instantly summarizes every submission—whether it’s the Ikena Oncology annual report 10-K simplified for pipeline updates, an Ikena Oncology quarterly earnings report 10-Q filing that breaks down trial costs, or an Ikena Oncology 8-K material events explained announcement about new data read-outs. Real-time feeds push Ikena Oncology Form 4 insider transactions real-time alerts so you never miss executive stock moves. Need granular detail? Interactive layers link straight to footnotes covering collaboration revenue or milestone payments.
Here’s what you can track in one place:
- “Ikena Oncology insider trading Form 4 transactions” including option exercises and open-market buys
- “Ikena Oncology proxy statement executive compensation” to compare pay with clinical progress
- “Ikena Oncology earnings report filing analysis” that benchmarks quarterly burn rate
- “Ikena Oncology executive stock transactions Form 4” patterns ahead of data releases
Every document arrives from EDGAR within seconds, then our AI surfaces trial timelines, Hippo and RAS program milestones, and any dilution risks buried in prospectus supplements. Stop scrolling through PDFs—get the biotech intelligence you need, the moment it’s filed.
Schedule 13D/A (Am. No. 5) — ImageneBio, Inc.
OrbiMed Advisors LLC and affiliated funds updated their stake following the 25 Jul 2025 1-for-12 reverse split and PIPE financing tied to the Ikena-Inmagene merger. Outstanding shares rose to 11,181,676, cutting the group’s ownership by >1 ppt to 773,754 shares (6.92%).
Break-down: OrbiMed Private Investments VI, LP holds 753,063 shares (6.73%); Worldwide Healthcare Trust PLC, advised by OrbiMed Capital LLC, owns 135,516 shares (1.21%); OrbiMed Genesis Master Fund, LP holds 20,691 shares (0.19%). Voting/dispositive power is largely shared among OrbiMed Advisors, OrbiMed Capital GP VI LLC, and OrbiMed Genesis GP LLC.
On 25 Jul 2025 OPI VI bought 83,611 PIPE shares at $2.49 each (≈$29.90 post-split); cash came from partnership working capital. The investors secured demand, piggy-back and Form S-3 registration rights; Director David P. Bonita’s equity awards are assigned to OrbiMed. The group states no present plans for further corporate actions but may trade shares opportunistically.
FAQ
What is the current stock price of Ikena Oncology (IKNA)?
What is the market cap of Ikena Oncology (IKNA)?
